Enhancing shareholder value through exceptional business performance and practices, and through responsible and effective communication with its shareholders.
The On-the-Go SARS-CoV-2 Testing Device System is under development as a point-of-care/patient-use device that includes a biosensor and an app intended as an aid in the diagnosis of COVID-19 infection. The system uses a nanohole array (NHA)-based plasmonic system being designed for high sensitivity and selectivity detection of SARS-CoV-2 virus. The device uses a thin sheet of gold coated with virus-specific proteins that can bind with SARS-CoV-2 virus. Once SARS-CoV-2 virus binds, the wavelength of light bouncing off the surface changes, creating a different color of light. This change in light color can be detected by a smartphone camera and an app with algorithms designed to detect SARS-CoV-2 virus. The test has the potential to provide results within minutes and the results can be sent to healthcare professionals or public health databases using the app on the patient’s mobile device.
The On-the-Go SARS-CoV-2 Testing Device System is currently under research stage of development (performance characteristics have not been established).
Hoth Therapeutics plans to initiate discussions with FDA in 2021 regarding development plans in pursuit of an Emergency Use Authorization request.